BioSpace News Archive

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, announced the presentation of initial clinical data from its ongoing trial evaluating evorpacept in combination with azacitidine for the treatment of patients with previously untreated higher-risk or relapsed or refractory myelodysplastic syndrome.

Nurix Therapeutics, Inc., a biopharmaceutical company developing targeted protein modulation drugs, announced the grant of a Clinical Trial Authorization for NX-5948, a potent and selective degrader of Bruton’s tyrosine kinase and the second drug candidate in Nurix’s BTK degradation program.

Global Blood Therapeutics, Inc. announced positive results from real-world and long-term studies with Oxbryta® tablets for the treatment of sickle cell disease.

Sangamo Therapeutics, Inc. announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 study of SAR445136, a zinc finger nuclease gene-edited cell therapy candidate in development with Sanofi for the treatment of sickle cell disease.

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company, announced updated clinical data from the pirtobrutinib global Phase 1/2 BRUIN clinical trial in patients with chronic lymphocytic leukemia, small lymphocytic lymphoma and mantle cell lymphoma.

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that updated initial safety and efficacy findings from the Phase 1b/2 study of IMGN632 in combination with Vidaza® and Venclexta® in patients with relapsed/refractory acute myeloid leukemia were presented in an oral session at the 63rd American Society of Hematology Annual Meeting.

ELEVATE-RR head-to-head trial data also presented at ASH showed patients on ibrutinib experienced a 37% higher burden of adverse events of any grade while on treatment vs. patients on CALQUENCE.

BeiGene announced results from a planned interim analysis of the Phase 3 SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia, including the randomized Cohort 1 comparing BRUKINSA to bendamustine plus rituximab and Cohort 3 of BRUKINSA in combination with venetoclax in patients with deletion of chromosome 17p and/or pathogenic TP53 variants.

Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, presented new preclinical data supporting the safety and efficacy profile of WU-CART-007 for T-cell malignancies.

Imago BioSciences, Inc., a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms, presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with essential thrombocythemia.